Analyzing Alkermes (NASDAQ:ALKS) & ULURU (OTCMKTS:ULUR)
Analyzing Alkermes (NASDAQ:ALKS) & ULURU (OTCMKTS:ULUR)
ULURU (OTCMKTS:ULUR – Get Rating) and Alkermes (NASDAQ:ALKS – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.
乌鲁鲁(OTCMKTS：ULUR-GET Rating)和艾尔建(纳斯达克：ALKS-GET Rating)都是医疗公司，但哪一家更好？我们将根据这两家公司分析师推荐的风险、股息、盈利能力、收益、估值和机构持股的强弱进行比较。
Risk & Volatility
风险与波动性
ULURU has a beta of -1.97, meaning that its share price is 297% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
乌鲁鲁的贝塔系数为-1.97，这意味着其股价的波动性比标准普尔500指数低297%。相比之下，Alkermes的贝塔系数为0.61，这意味着其股价的波动性比标准普尔500指数低39%。
Analyst Recommendations
分析师建议
This is a summary of recent ratings for ULURU and Alkermes, as reported by MarketBeat.com.
这是MarketBeat.com报道的乌鲁鲁和阿尔克姆斯最近的评级摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ULURU | 0 | 0 | 0 | 0 | N/A |
| Alkermes | 0 | 4 | 4 | 0 | 2.50 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 乌鲁鲁 | 0 | 0 | 0 | 0 | 不适用 |
| 阿尔克梅斯 | 0 | 4 | 4 | 0 | 2.50 |
Insider & Institutional Ownership
内部人与机构所有权
94.8% of Alkermes shares are held by institutional investors. 1.1% of ULURU shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Alkermes 94.8%的股份由机构投资者持有。乌鲁鲁1.1%的股份由公司内部人士持有。相比之下，Alkermes 4.8%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、大型基金管理公司和捐赠基金相信，一只股票有望实现长期增长。
Earnings & Valuation
收益与估值
This table compares ULURU and Alkermes' top-line revenue, earnings per share and valuation.
该表格比较了乌鲁鲁和阿尔克梅斯的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ULURU | N/A | N/A | N/A | N/A | N/A |
| Alkermes | $1.17 billion | 3.46 | -$48.17 million | ($0.78) | -31.67 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 乌鲁鲁 | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
| 阿尔克梅斯 | 11.7亿美元 | 3.46 | -4,817万元 | ($0.78) | -31.67 |
ULURU has higher earnings, but lower revenue than Alkermes.
乌鲁鲁的收益比Alkermes高，但营收比Alkermes低。
Profitability
盈利能力
This table compares ULURU and Alkermes' net margins, return on equity and return on assets.
此表比较了Uluru和Alkermes的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| ULURU | N/A | N/A | N/A |
| Alkermes | -11.41% | -1.10% | -0.60% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 乌鲁鲁 | 不适用 | 不适用 | 不适用 |
| 阿尔克梅斯 | -11.41% | -1.10% | -0.60% |
Summary
摘要
Alkermes beats ULURU on 6 of the 9 factors compared between the two stocks.
阿尔克梅斯在两只股票比较的9个因素中有6个击败了乌鲁鲁。
About ULURU
关于乌鲁鲁
(Get Rating)
(获取评级)
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.
乌鲁鲁公司是一家专业医疗技术公司，基于其在美国和国际上获得专利的Nanoflex和OraDisc技术，研究、开发和销售一系列伤口护理和粘合剂薄膜产品。该公司提供Altrazeal，这是一种变形粉末敷料，用于治疗各种伤口，如部分深度烧伤、供体部位、手术和创伤伤口，以及慢性伤口，包括糖尿病足、静脉腿和压疮。其产品还包括用于治疗溃烂疮的Aphthasol糊剂；用于治疗溃烂疮的OraDisc A；以及用于治疗和管理口腔疼痛的OraDisc B。乌鲁鲁公司，总部设在德克萨斯州的艾迪森。
About Alkermes
关于阿尔克姆斯
(Get Rating)
(获取评级)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc是一家生物制药公司，研究、开发和商业化药物产品，以满足美国、爱尔兰和国际上不同治疗领域患者未得到满足的医疗需求。其销售的产品包括用于治疗精神分裂症的肌肉注射混悬剂Aristada；用于治疗酒精和防止阿片类药物依赖的VIVITROL；用于治疗精神分裂症和双相I型障碍的Risperdal Consta；用于治疗精神分裂症和分裂情感障碍的INVEGA SUSTENNA；用于治疗精神分裂症和分裂情感障碍的XEPLION、INVEGA TRINZA和TREVICTA；以及用于治疗成人复发形式的多发性硬化症的VUMERITY，包括临床孤立综合征、复发缓解和活跃的继发性进行性疾病。该公司还在开发LYBALVI，一种用于治疗成人精神分裂症和双相I型障碍的口服非典型抗精神病药物候选药物；以及nemvaleukin alfa，一种工程融合蛋白，用于扩大肿瘤杀伤免疫细胞，避免免疫抑制细胞的激活。它主要与Janssen制药公司、Janssen制药公司和Janssen制药国际公司签订了合作协议。Alkermes plc成立于1987年，总部设在爱尔兰都柏林。
Receive News & Ratings for ULURU Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ULURU and related companies with MarketBeat.com's FREE daily email newsletter.
接受《乌鲁鲁日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Uluru和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。